FRANCE – French medtech startup Kayentis has announced the launch of an integrated patient-centric platform that optimizes the management of hybrid and Decentralized Clinical Trials (DCT).
This streamlined platform alleviates many logistical hurdles in bringing key elements of the clinical trial to patients’ homes, while vastly improving how patients and sites use DCT technologies.
Stakeholders in remote clinical trials gain seamless access to a wide panel of robust functionalities all within the same platform.
These include various modes of data collection, such as BYOD, WebCOA, provisioned devices, and data entry by phone; as well as an easy-to-use telemedicine app.
Embedded features that enable active patient engagement are also included, with options to integrate other functions in the future.
“Kayentis’ new streamlined platform features make remote clinical trials much easier for patients, sites, CROs and sponsors to manage; the simplified access to options considerably reduces patient burden,” said Guillaume Juge, CEO at Kayentis.
“We have been expanding our DCT services in step with the growing demand for hybrid and decentralized clinical trials. This added capacity enables our operational teams across Europe, the US and Asia to attract wider interest in our digital capabilities.”
The pandemic sped up the timeline in the transition towards Decentralized Clinical Trials with patients more readily embracing remote technologies.
For Kayentis, simplifying the access to and streamlining the management of functionalities is key to this digital transformation.
Benefits of Kayentis’ patient-centric platform for DCT
The company considers that its fully integrated platform offers a significant advantage over using a combination of various functionalities sourced from different suppliers.
The digital platform alleviates some of the logistical and physical burdens that clinical trials can impose on both research sites and patients.
Kayentis has stripped out this complexity, opting to work from the bottom up to ensure that the many functions interconnect smoothly.
By 2027, the global eCOA market is expected to be worth US$2.6 billion, as per Data Bridge Market Research.
Kayentis’ product is an example of electronic Clinical Outcome Assessment (eCOA), a method of electronically collecting outcomes data in clinical trials.
For sponsors, the fully integrated platform enables a single set-up of all functionalities that better facilitate sponsor lead times.
Finally, for pharma and biotech companies, this improves retention rates, improves study data quality, and satisfies regulatory requirements.
“Kayentis’ platform is applicable in all therapeutic areas, particularly complex protocols, and in all clinical trial models: traditional, virtual or hybrid clinical trials.
The value in this new platform lies in its ability to expand the choice of interconnectable options, while standardizing the same enhanced user experience across multiple systems (Web, Google Android, Apple iOS),” said Martial Marcotti, product marketing director at Kayentis.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
